Aspen Aerogels, Inc. (NYSE: ASPN) stock plunged -1.8% and closed at 4.36 in most recent trading session. The stock opened the session at $4.45 and touched its highest price point at $4.49. Its recent trading capacity is 14261 shares versus to its average trading volume of 48231 shares. The company’s stock’s lowest price point for the session stood at $4.35.ASPN traded as low as $ 3.84 in the past 52 weeks, and shares hit its peak level to $5.58.
Aspen Aerogels, Inc. (NYSE:ASPN) recently declared financial results for the fourth quarter and full year 2017, which ended December 31, 2017, and discussed business developments during the quarter.
Total revenue for the fourth quarter was $36.4 million compared to $27.6 million in the fourth quarter last year. Fourth quarter net loss was $1.7 million compared to $5.7 million in the fourth quarter of 2016. Net loss per share for the quarter was $0.07 compared to $0.25 in the fourth quarter last year.
Total revenue for the full year was $111.6 million compared to $117.7 million in 2016. Net loss for the year was $19.3 million compared to $12.0 million last year. Net loss per share for the year was $0.83 per share compared to $0.52 per share in 2016.
Adjusted EBITDA for the fourth quarter was $2.2 million compared to $(2.1) million in the fourth quarter of 2016. Adjusted EBITDA for the full year was $(3.3) million compared to $3.9 million in 2016. A reconciliation of non-GAAP Adjusted EBITDA to net loss is provided in the financial schedules that are part of this press release. An explanation of this non-GAAP financial measure is also included below under the heading “Non-GAAP Financial Measures.”
Net loss and Adjusted EBITDA included legal and related expenses associated with Aspen Aerogels’ ongoing patent enforcement actions of $0.6 million for the fourth quarter compared to $1.9 million in the fourth quarter of 2016 and $3.5 million for the full year compared to $3.6 million in 2016.
2018 Financial Outlook
Aspen Aerogels issues its 2018 full year outlook as follows:
Total revenue is expected to range between $106 million and $116 million
Net loss is expected to range between $16.9 million and $20.0 million
Adjusted EBITDA is expected to range between $(2.0) million and $(5.0) million
Net loss per share is expected to range between $(0.71) and $(0.85)
Our 2018 outlook assumes depreciation and amortization of $10.3 million, stock-based compensation expense of $4.3 million, interest and other expense of $0.3 million, and weighted average shares outstanding of 23.6 million for the full year. In addition, our 2018 outlook reflects an expected $1.1 million to $1.3 million of costs and expenses associated with our ongoing patent enforcement efforts during the year.
Aspen Aerogels may incur charges, realize gains or losses, incur financing costs or interest expense, or experience other events in 2018 that could cause actual results to vary materially from this outlook. In addition, the timing of projects may have a significant impact on quarterly and annual revenue and profitability and can be difficult to predict.